| Name | Title | Contact Details |
|---|---|---|
Ed Mangis |
Executive Vice President and Chief Learning and Talent Development Officer | Profile |
Kathryn Kenney |
VP, Talent Acquisition | Profile |
Allison Spriggs |
Vice President, Talent Acquisition | Profile |
Leslie Simpson |
EVP, Talent Acquisition Strategy | Profile |
Richard Garcia |
Chief Talent Officer for North America | Profile |
Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Transforming the economics, usability, and accessibility of Endoscopic Ultrasound (EUS) for the benefit of patients, physicians, and payers.
Immune-Tree Inc is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
physIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both clinical trial support and healthcare, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies
The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.